Loading…
APO-TERIFLUNOMIDE is a brand name for Teriflunomide, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: , 1.1 Pediatrics 02/2023 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 02/2023 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations 02/2023 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment 02/2023 7 WARNINGS AND PRECAUTIONS, Cardiovascular 02/2023 7 WARNINGS AND PRECAUTIONS,…
Verbatim from this product's HC label. Tap a section to expand.
3 Pediatric 01/2024 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES .............................................................................................
2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................
4 1 INDICATIONS .................................................................................................................. 1 Pediatrics ....................................................................................................................
2 Geriatrics .................................................................................................................... 4 2 CONTRAINDICATIONS .....................................................................................................
4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................................ 5 4 DOSAGE AND ADMINISTRATION .................................................................................... 1 Dosing Considerations ................................................................................................
2 Recommended Dose and Dosage Adjustment ........................................................... 5 Missed Dose ............................................................................................................... 7 5 OVERDOSAGE .................................................................................................................
7
). The majority of patients recovered from decreased neutrophils and/or lymphocyte cell counts in less than 8 weeks, whether continuing on teriflunomide or after discontinuation. Rare cases of pancytopenia, agranulocytosis and thrombocytopenia have been reported in the postmarketing setting with leflunomide.
A similar risk is expected for teriflunomide. Obtain a complete blood cell count (CBC) within 6 months before initiating treatment with APO- TERIFLUNOMIDE and periodically during treatment. Further monitoring should be based on signs and symptoms suggestive of infection.
In any situation in which the decision is made to switch to or from APO-TERIFLUNOMIDE, from or to another agent with a known potential for hematologic suppression, monitoring for hematologic toxicity is recommended, because there will be overlap of systemic exposure to both compounds, due to the slow elimination from plasma of teriflunomide and some of the other therapies (eg, natalizumab, fingolimod).
3 Pharmacokinetics; 7 WARNINGS AND PRECAUTIONS, Accelerated Elimination Procedure). In patients with pre-existing anemia, leucopenia, and/or thrombocytopenia as well as in APO-TERIFLUNOMIDE (Teriflunomide tablets) Page 10 of 51 patients with impaired bone marrow function or those at risk of bone marrow suppression, the risk of hematological disorders is increased.
If such effects occur, the accelerated elimination procedure should be considered. Hepatic/Biliary/Pancreatic Hepatic Liver function abnormalities have been reported in some patients treated with teriflunomide in clinical trials. Severe liver injury including fatal liver failure occurred rarely in the post marketing setting.
Patients with pre-existing liver disease may be at increased risk of developing elevated serum transaminases when taking APO-TERIFLUNOMIDE. Patients with pre-existing acute or chronic liver disease, or those with serum alanine aminotransferase (ALT) greater than two times the upper limit of normal (ULN) before initiating treatment, should not normally be treated with APO-TERIFLUNOMIDE.
3 Pediatric 01/2024 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES .............................................................................................
2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................
4 1 INDICATIONS .................................................................................................................. 1 Pediatrics ....................................................................................................................
2 Geriatrics .................................................................................................................... 4 2 CONTRAINDICATIONS .....................................................................................................
4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................................ 5 4 DOSAGE AND ADMINISTRATION .................................................................................... 1 Dosing Considerations ................................................................................................
2 Recommended Dose and Dosage Adjustment ........................................................... 5 Missed Dose ............................................................................................................... 7 5 OVERDOSAGE .................................................................................................................
7 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .................................... 7 7 WARNINGS AND PRECAUTIONS ..................................................................................... 1 Special Populations ................................................................................................
APO-TERIFLUNOMIDE (teriflunomide) is contraindicated in patients: ▪ with known hypersensitivity to teriflunomide, leflunomide (the parent compound) or to any of the nonmedicinal ingredients in the formulation. ▪ who are currently treated with leflunomide.
Co-administration of teriflunomide with leflunomide is contraindicated. ▪ with severe hepatic impairment (see 7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic). ▪ who are pregnant or women of childbearing potential not using reliable contraception (see 7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and Male Potential).
APO-TERIFLUNOMIDE may cause fetal harm when administered to a pregnant woman. Pregnancy must be excluded before start of treatment. g. AIDS). ▪ with impaired bone marrow function or significant anemias, leucopenia, neutropenia or thrombocytopenia.
APO-TERIFLUNOMIDE (Teriflunomide tablets) Page 5 of 51 ▪ with serious active infections.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Teriflunomide in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
APO-TERIFLUNOMIDE is contraindicated in patients with severe hepatic impairment (see 2 CONTRAINDICATIONS). Elevations of liver enzymes have been observed in patients receiving teriflunomide. 7%) of patients on placebo, during the treatment period of up to 2 years.
These elevations occurred mostly within the first 6 months of treatment. Half of the cases returned to normal without drug discontinuation. In clinical trials, teriflunomide was discontinued if the ALT elevation exceeded 3 times the ULN on two consecutive tests.
Of the patients who underwent discontinuation of teriflunomide and accelerated elimination in controlled trials, serum transaminase levels returned to normal within approximately 2 months. In controlled clinical trials, one serious case of “toxic hepatitis” was reported in a 35-year-old female patient.
The patient developed ALT 32 times the ULN and jaundice 5 months after initiation of teriflunomide 14 mg treatment. The patient was hospitalized for 5 weeks and recovered after plasmapheresis and cholestyramine accelerated elimination procedure.
Although the etiology of the hepatic event remained unclear, a causal role of teriflunomide in this case is possible. 5 Post-Market Adverse Reactions). The time to onset of DILI ranged from days to years after initiating treatment with teriflunomide.
Drug-induced liver injury events were reported in patients with and without relevant risk factors, such as a history of drug-induced hepatotoxicity or concomitant use of other hepatotoxic drugs, including some drugs used for managing multiple sclerosis.
Due to the potential for severe liver injury, exercise caution and closely monitor patients if other known or potentially hepatotoxic drugs are used in combination with APO-TERIFLUNOMIDE or if there is APO-TERIFLUNOMIDE (Teriflunomide tablets) Page 11 of 51 a history of drug-induced hepatotoxicity (see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX, Hepatotoxicity and Risk of Teratogenicity).
For all patients, obtain serum transaminase and bilirubin levels within 6 months before initiating treatment with APO-TERIFLUNOMIDE. Monitor ALT levels at least monthly for at least six months after starting APO-TERIFLUNOMIDE. Additional monitoring is recommended if APO- TERIFLUNOMIDE is used with other potentially hepatotoxic drugs or if there is a history of drug-induced hepatotoxicity.
Consider discontinuing APO-TERIFLUNOMIDE if serum transaminase increase (greater than three times the ULN) is confirmed. Monitor serum transaminase and bilirubin on APO-TERIFLUNOMIDE therapy, particularly in patients who develop symptoms suggestive of hepatic dysfunction, such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine.
Patients should be advised to immediately report signs or symptoms of hepatotoxicity. If liver injury is suspected to be teriflunomide-induced, discontinue APO-TERIFLUNOMIDE and start an accelerated elimination procedure (see 7 WARNINGS AND PRECAUTIONS, General, Accelerated Elimination Procedure) and monitor liver tests weekly until normalized.
If teriflunomide-induced liver injury is unlikely because some other probable cause has been found, resumption of teriflunomide therapy may be considered. Due to a potential for additive hepatotoxic effects, alcohol consumption should be avoided during treatment with APO-TERIFLUNOMIDE.
[…]
1 Pregnant Women ................................................................................................... 2 Breast-feeding ........................................................................................................
3 Pediatrics................................................................................................................ 4 Geriatrics ................................................................................................................
18 8 ADVERSE REACTIONS .................................................................................................... 1 Adverse Reaction Overview ......................................................................................
2 Clinical Trial Adverse Reactions ................................................................................ 4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data .....................................................................................................
5 Post-Market Adverse Reactions ............................................................................... 23 9 DRUG INTERACTIONS ...................................................................................................
2 Drug Interactions Overview ...................................................................................... 4 Drug-Drug Interactions .............................................................................................
5 Drug-Food Interactions............................................................................................. 6 Drug-Herb Interactions .............................................................................................
7 Drug-Laboratory Test Interactions............................................................................ 28 10 CLINICAL PHARMACOLOGY ........................................................................................... 1 Mechanism of Action ................................................................................................
2 Pharmacodynamics .................................................................................................. 3 Pharmacokinetics .....................................................................................................
29 11 STORAGE, STABILITY AND DISPOSAL............................................................................. 32 12 SPECIAL HANDLING INSTRUCTIONS .............................................................................. 32 PART II: SCIENTIFIC INFORMATION ........................................................................................
33 13 PHARMACEUTICAL INFORMATION ............................................................................... 33 14 CLINICAL TRIALS ...........................................................................................................
1 Clinical Trials by Indication ..................................................................................... 2 Comparative Bioavailability Studies ....................................................................... 39 15 MICROBIOLOGY ............................................................................................................
40 16 NON-CLINICAL TOXICOLOGY ......................................................................................... 40 17 SUPPORTING PRODUCT MONOGRAPHS […]